SUPN

SUPERNUS PHARMACEUTICALS, INC.

Pharmaceutical Preparations · SIC 2834CIK 1356576Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.72B

Net Income FY2025

$(0.04B)

EPS (Basic, as reported)

$-0.68

Net Margin FY2025

-5.4%

ROE FY2025

-3.6%

Total Equity

$1.06B

Shares Out

58M

Business description

SUPERNUS PHARMACEUTICALS, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2010–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 215 → 719 +14.4% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue215302409393520580667608662719

Cost of revenue(12)(15)(15)(17)(52)(75)(87)(84)(78)(75)

Research & development(43)(50)(89)(69)(76)(90)(75)(92)(109)(106)

Selling, general & administrative(106)(138)(160)(158)(201)(305)(377)(336)(322)(486)

Total operating expenses(161)(203)(264)(244)(347)(494)(621)(613)(580)(781)

Operating income541001441491748646(5)82(62)

Interest expense(1)0(14)(18)(19)(20)(7)(2)00

Interest & investment income1314———————

Other income (expense), net(4)1(4)(1)(5)(13)1581613

Pre-tax income501011401471697361398(49)

Income tax expense(41)(43)(29)(34)(42)(20)0(1)(24)(10)

Net income91571111131275361174(39)

EPS — basic$1.84$1.13$2.13$2.16$2.41$1.01$1.13$0.02$1.34($0.68)

EPS — diluted$1.76$1.08$2.05$2.10$2.36$0.98$1.04$0.02$1.32($0.68)

Shares outstanding — basic (M)49515252535354555556

Shares outstanding — diluted (M)52535454545462565656

Showing the latest 10 of 16 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.